Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents

Current Oncology Reports

Volumn 7, Issue 2, 2005, Pages 116-122

  Desai, Apurva A ^a   Stadler, Walter M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR;

ALOPECIA; BLEEDING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DIARRHEA; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; EPISTAXIS; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; NAUSEA; NONHUMAN; PROTEINURIA; REVIEW; THROMBOEMBOLISM;

EID: 16844375094     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0037-6     Document Type: Review

References (54)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
2. Reuter VE, Presti JC Jr: Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 2000, 27:124-137.
3. Beck SD, Patel MI, Snyder ME, et al.: Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004, 11:71-77.
4. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408-417.
5. Stadler WM, Huo D, George C, et al.: Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 2003, 170:1141-1145.
6. Stadler WM, Halabi S, Ernstoff MS, et al.: A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B #90008 [abstract]. J Clin Oncol 2004, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22 (15 Suppl):4515.
7. Yang JC, Sherry RM, Steinberg SM, et al.: Randomized study of high dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003, 21:3127-3132.
8. Coppin C, Porzsolt F, Kumpf J, et al.: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000:CD001425.
9. Vogelzang NJ, Stadler WM: Kidney cancer [see comments]. Lancet 1998, 352:1691-1696.
10. Dinney CP, Bielenberg DR, Perrotte P, et al.: Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by Systemic interferon-alpha administration. Cancer Res 1998, 58: 08-814.
11. Maynard MA, Ohh M: von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 2004, 24:1-13.
12. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004, 10:6290S-6295S.
13. Herman JG, Latif F, Weng Y, et al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994, 91:9700-9704.
14. Gnarra JR, Tory K, Weng Y, et al.: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7:85-90.
15. Gnarra JR, Duan DR, Weng Y, et al.: Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta 1996, 1242:201-210.
16. Iliopoulos O, Levy AP, Jiang C, et al.: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996, 93:10595-10599.
17. Maxwell PH, Wiesener MS, Chang GW, et al.: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
18. Turner KJ, Moore JW, Jones A, et al.: Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002, 62:2957-2961.
19. Wang YQ, Luk JM, Ikeda K, et al.: Regulatory role of vHL/HIF-1a in hypoxia-induced VEGF production in hepatic stellate cells. Biochem Biophys Res Commun 2004, 317:358-362.
20. Wykoff CC, Beasley NJ, Watson PH, et al.: Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000, 60:7075-7083.
21. Presta LG, Chen H, O'Connor SJ, et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
22. Gordon MS, Margolin K, Talpaz M, et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19:843-850.
23. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
24. Rini BI, Halabi S, Taylor J, et al.: Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon or interferon plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004, 10:2584-2586.
25. Wilhelm S, Carter C, Tang LY, et al.: BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis [abstract]. Presented at the International Conference on Molecular Targets and Cancer Therapeutics, AACR-NCI-EORTC Proc 2003; A78.
26. Strumberg D, Voliotis D, Moeller JG, et al.: Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumours. Int J Clin Pharmacol Ther 2002, 40:580-581.
27. Rosner GL, Stadler WM, Ratain MJ: Randomized discontinuation design: application to cytostatic anti-neoplastic agents. J Clin Oncol 2002, 22:4478-4484.
28. Ratain MJ, Flaherty KT, Stadler WM, et al.: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial [abstract]. J Clin Oncol 2004, 22:382 (abst 4501).
29. Bayer and Onyx corporation press release. Accessible at http://biz.yahoo.com/prnews/041025/nym036 1.html
30. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cnacer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
31. Rosen L, Mulay M, Long J, et al.: Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors [abstract]. Proc ASCO 2003, 22:765.
32. Mendel DB, Laird AD, Xin X, et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
33. Motzer RJ, Rini BI, Michaelson MD, et al.: SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase 2 trial [abstract]. J Clin Oncol 2004, 22: 820.
34. Salomon DS, Brandt R, Ciardiello F, et al.: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haem, 1995, 19:183-232.
35. Grandis JR, Sok JC: Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004, 102:37-46.
36. Yoshida K, Tosaka A, Takeuchi S, et al.: Epidermal growth factor receptor content in human renal cell carcinomas. Cancer 1994, 73:1913-1918.
37. Drucker B, Bacik J, Ginsberg M, et al.: Phase II trial of ZD1839 in patients with advanced renal cell carcinoma. Invest New Drugs 2003, 21:341-345.
38. Motzer R, Amato R, Todd M, et al.: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003, 21: 9-101.
39. Hainsworth JD, Sosman JA, Spigel DR, et al.: Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC) [abstract]. J Clin Oncol 2004, 22:382.
40. Herbst RS, Prager D, Hermann R, et al.: TRIBUTE - A phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2004, 22:7011.
41. Gatzemeier U, Pluzanska A, Szczesna A, et al.: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2004, 22(14S): 010.
42. Giaccone G, Johnson D, Scagliotti GV, et al.: Results of a multi-variate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large phase III trials (INTACT 1 and 2) [abstract]. Proc ASCO 2003, 22:2522.
43. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351: 37-345.
44. Shepherd FA, Pereira J, Ciuleanu TE, et al.: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy [abstract]. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol 2004, 22:7022.
45. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
46. Cobleigh MA, Vogel CL, Tripathy D, et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
47. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
48. Paez JG, Janne PA, Lee JC, et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
49. Guilhot F: Indications for imatinib mesylate therapy and clinical management. Oncologist 2004, 9:271-281.
50. Gayed I, Vu T, Iyer R, et al.: The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004, 45: 7-21.
51. Morgan B, Thomas AL, Drevs J, et al.: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003, 21:3955-3964.
52. Salomon AR, Ficarro SB, Brill LM, et al.: Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry. Proc Natl Acad Sci U S A 2003, 100:443-448.
53. Shai R, Shi T, Kremen TJ, et al.: Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 2003, 22:4918-4923.
54. Schwartz LH, Mazumdar M, Wang L, et al.: Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. Cancer 2003, 98:1611-1619.